Proteomic and phosphoproteomic analysis of chicken embryo fibroblasts infected with cell culture-attenuated and vaccine strains of marek's disease virus

Journal of Proteome Research

Volumn 11, Issue 12, 2012, Pages 5663-5677

  Chien, Ko Yi ^a   Blackburn, Kevin ^a   Liu, Hsiao Ching ^a   Goshe, Michael B ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

liquid chromatography; Marek's Disease Virus; mass spectrometry; phosphoproteomics; phosphorylation; proteomics

Indexed keywords

MAREK DISEASE VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHICK EMBRYO; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENOMICS; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MARDIVIRUS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TRANSCRIPTION INITIATION; TRANSLATION INITIATION; VIRUS IMMUNITY; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CHICK EMBRYO; CHROMATOGRAPHY, AFFINITY; EUKARYOTIC INITIATION FACTOR-4E; FIBROBLASTS; HERPESVIRUS 2, GALLID; MAREK DISEASE; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PHOSPHOPEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOME; PROTEOMICS; TRANSCRIPTION, GENETIC; VIRAL PLAQUE ASSAY;

AVES; GALLID HERPESVIRUS 2; GALLUS GALLUS;

EID: 84870938777     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300471y     Document Type: Article

References (77)

1. Witter, R. L. Characteristics of Marek's disease viruses isolated from vaccinated commercial chicken flocks: association of viral pathotype with lymphoma frequency Avian Dis. 1983, 27, 113-32
2. Witter, R. L. Increased virulence of Marek's disease virus field isolates Avian Dis. 1997, 41, 149-63
3. Witter, R. L.; Calnek, B. W.; Buscaglia, C.; Gimeno, I. M.; Schat, K. A. Classification of Marek's disease viruses according to pathotype: philosophy and methodology Avian Pathol. 2005, 34, 75-90
4. Churchill, A. E.; Chubb, R. C.; Baxendale, W. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture J. Gen. Virol. 1969, 4, 557-64
5. Rispens, B. H.; van Vloten, H.; Mastenbroek, N.; Maas, H. J.; Schat, K. A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials Avian Dis. 1972, 16, 108-25
6. Rispens, B. H.; van Vloten, H.; Mastenbroek, N.; Maas, J. L.; Schat, K. A. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus Avian Dis. 1972, 16, 126-38
7. Chien, K.; Liu, H.; Goshe, M. B. Development and application of a phosphoproteomic method using electrostatic repulsion-hydrophilic interaction chromatography (ERLIC), IMAC, and LC-MS/MS analysis to study Marek's Disease Virus infection J. Proteome Res. 2011, 10, 4041-53
8. Witter, R. L. Attenuated revertant serotype 1 Marek's disease viruses: safety and protective efficacy Avian Dis. 1991, 35, 877-91
9. Witter, R. L. Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus Avian Pathol. 1982, 11, 49-62
10. Witter, R. L.; Silva, R. F.; Lee, L. F. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: selected biological and molecular characteristics Avian Dis. 1987, 31, 829-40
11. Witter, R. L.; Lee, L. F. Polyvalent Marek's disease vaccines: safety, efficacy and protective synergism in chickens with maternal antibodies Avian Pathol. 1984, 13, 75-92
12. Biggs, P.. M.; Milne, B. S. Biological properties of a number of Marek's disease virus isolates. In Oncogegesis and Herpesviruses; International Agency for Research on Cancer: Lyon, France, 1972; pp 88-94.
13. Jurajda, V.; Halouzka, R. Isolation and study of biological properties of non-oncogenic Marek's disease herpesviruses in chickens. 1. Characterization in vitro Vet. Med. 1992, 37, 531-4
14. Witter, R. L. New serotype 2 and attenuated serotype 1 Marek's Disease vaccine viruses: comparative efficacy Avian Dis. 1987, 31, 752
15. Witter, R. L. Control strategies for Marek's Disease: a perspective for the future pathotypes and evolution of MD vaccines: current technology Poult. Sci. 1998, 77, 1197-1203
16. Majerc, V.; Ney, E.; Kingham, B. F.; Kopa, J.; Schmidt, C. J. The genome of herpesvirus of turkeys: comparative analysis with Marek s disease viruses J. Gen. Virol. 2001, 82, 1123-1135
17. Osterrieder, N.; Kamil, J. P.; Schumacher, D.; Tischer, B. K.; Trapp, S. Marek's disease virus: from miasma to model Nat. Rev. Microbiol. 2006, 4, 283-94
18. Sondermeijer, P. J.; Claessens, J. A.; Jenniskens, P. E.; Mockett, A. P.; Thijssen, R. A.; Willemse, M. J.; Morgan, R. W. Avian herpesvirus as a live viral vector for the expression of heterologous antigens Vaccine 1993, 11, 349-58
19. McMillen, J. K.; Cochran, M. D.; Junker, D. E.; Reddy, D. N.; Valencia, D. M. The safe and effective use of fowlpox virus as a vector for poultry vaccines Dev. Biol. Stand. 1994, 82, 137-45
20. Nazerian, K.; Witter, R. L.; Lee, L. F.; Yanagida, N. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus Avian Dis. 1996, 40, 368-76
21. Ross, L. J.; Binns, M. M.; Tyers, P.; Pastorek, J.; Zelnik, V.; Scott, S. Construction and properties of a turkey herpesvirus recombinant expressing the Marek's disease virus homologue of glycoprotein B of herpes simplex virus J. Gen. Virol. 1993, 74 (Pt 3) 371-7
22. Ross, N.; O'Sullivan, G.; Coudert, F. Influence of chicken genotype on protection against Marek's disease by a herpesvirus of turkeys recombinant expressing the glycoprotein B (gB) of Marek's disease virus Vaccine 1996, 14, 187-9
23. Tarpey, I.; Davis, P. J.; Sondermeijer, P.; van Geffen, C.; Verstegen, I.; Schijns, V. E. J. C.; Kolodsick, J.; Sundick, R. Expression of chicken interleukin-2 by turkey herpesvirus increases the immune response against Marek's disease virus but fails to increase protection against virulent challenge Avian Pathol. 2007, 36, 69-74
24. Lambeth, L. S.; Zhao, Y.; Smith, L. P.; Kgosana, L.; Nair, V. Targeting Marek's disease virus by RNA interference delivered from a herpesvirus vaccine Vaccine 2009, 27, 298-306
25. Lee, L. F.; Lupiani, B.; Silva, R. F.; Kung, H.-J.; Reddy, S. M. Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV Vaccine 2008, 26, 1887-92
26. Tischer, B. K.; Schumacher, D.; Beer, M.; Beyer, J.; Teifke, J. P.; Osterrieder, K.; Wink, K.; Zelnik, V.; Fehler, F.; Osterrieder, N. A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens J. Gen. Virol. 2002, 83, 2367-76
27. Lee, L. F.; Bacon, L. D.; Yoshida, S.; Yanagida, N.; Zhang, H. M.; Witter, R. L. The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype Avian Dis. 2004, 48, 129-37
28. Tsukamoto, K.; Kojima, C.; Komori, Y.; Tanimura, N.; Mase, M.; Yamaguchi, S. Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2 Virology 1999, 257, 352-62
29. Sakaguchi, M.; Nakamura, H.; Sonoda, K.; Okamura, H.; Yokogawa, K.; Matsuo, K.; Hira, K. Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1 Vaccine 1998, 16, 472-9
30. Morgan, R. W.; Gelb, J.; Schreurs, C. S.; Lütticken, D.; Rosenberger, J. K.; Sondermeijer, P. J. Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein Avian Dis. 1992, 36, 858-70
31. Heckert, R. A.; Riva, J.; Cook, S.; McMillen, J.; Schwartz, R. D. Onset of protective immunity in chicks after vaccination with a recombinant herpesvirus of turkeys vaccine expressing Newcastle disease virus fusion and hemagglutinin-neuraminidase antigens Avian Dis. 1996, 40, 770-7
32. Tarpey, I.; van Loon, A. A.; de Haas, N.; Davis, P. J.; Orbell, S.; Cavanagh, D.; Britton, P.; Casais, R.; Sondermeijer, P.; Sundick, R. A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virus Vaccine 2007, 25, 8529-35
33. Silva, R. F.; Dunn, J. R.; Cheng, H. H.; Niikura, M. A MEQ-deleted Marek's disease virus cloned as a bacterial artificial chromosome is a highly efficacious vaccine Avian Dis. 2010, 54, 862-9
34. Ono, K.; Takashima, M.; Ishikawa, T.; Hayashi, M.; Yoshida, I.; Konobe, T.; Ikuta, K.; Nakajima, K.; Ueda, S.; Kato, S. Partial protection against Marek's disease in chickens immunized with glycoproteins gB purified from turkey-herpesvirus-infected cells by affinity chromatography coupled with monoclonal antibodies Avian Dis. 1985, 29, 533-9
35. Ikuta, K.; Ueda, S.; Kato, S.; Hirai, K. Processing of glycoprotein gB related to neutralization of Marek's disease virus and herpesvirus of turkeys Microbiol. Immunol. 1984, 28, 923-33
36. Santin, E. R.; Shamblin, C. E.; Prigge, J. T.; Arumugaswami, V.; Dienglewicz, R. L.; Parcells, M. S. Examination of the effect of a naturally occurring mutation in glycoprotein L on Marek's disease virus pathogenesis Avian Dis. 2006, 50, 96-103
37. Tavlarides-Hontz, P.; Kumar, P. M.; Amortegui, J. R.; Osterrieder, N.; Parcells, M. S. A deletion within glycoprotein L of Marek's disease virus (MDV) field isolates correlates with a decrease in bivalent MDV vaccine efficacy in contact-exposed chickens Avian Dis. 2009, 53, 287-96
38. Kano, R.; Konnai, S.; Onuma, M.; Ohashi, K. Cytokine profiles in chickens infected with virulent and avirulent Marek's disease viruses: interferon-gamma is a key factor in the protection of Marek's disease by vaccination Microbiol. Immunol. 2009, 53, 224-32
39. Haq, K.; Abdul-Careem, M. F.; Shanmuganthan, S.; Thanthrige-Don, N.; Read, L. R.; Sharif, S. Vaccine-induced host responses against very virulent Marek's disease virus infection in the lungs of chickens Vaccine 2010, 28, 5565-72
40. Glaubiger, C.; Nazerian, K.; Velicer, L. F. Marek's disease herpesviruses. IV. Molecular characterization of Marek's disease herpesvirus A antigen J. Virol. 1983, 45, 1228-34
41. Cheng, F.; Blackburn, K.; Lin, Y.; Goshe, M. B.; Williamson, J. D. Absolute protein quantification by LC-MS(E) for global analysis of salicylic acid-induced plant protein secretion responses J. Proteome Res. 2009, 8, 82-93
42. Zhu, W.; Cai, M.-Y.; Tong, Z.-T.; Dong, S.-S.; Mai, S.-J.; Liao, Y.-J.; Bian, X.-W.; Lin, M. C.; Kung, H.-F.; Zeng, Y.-X.; Guan, X.-Y.; Xie, D. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition Gut 2012, 61, 562-75
43. Lee, N. P.; Tsang, F. H.; Shek, F. H.; Mao, M.; Dai, H.; Zhang, C.; Dong, S.; Guan, X.; Poon, R. T. P.; Luk, J. M. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma Int. J. Cancer 2010, 127, 968-76
44. Marchet, A.; Mocellin, S.; Belluco, C.; Ambrosi, A.; DeMarchi, F.; Mammano, E.; Digito, M.; Leon, A.; D'Arrigo, A.; Lise, M.; Nitti, D. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status Ann. Surg. Oncol. 2007, 14, 1058-64
45. Lee, Y. J.; Glaunsinger, B. A. Aberrant herpesvirus-induced polyadenylation correlates with cellular messenger RNA destruction PLoS Biol. 2009, 7, e1000107
46. Katzenellenbogen, R. A.; Vliet-Gregg, P.; Xu, M.; Galloway, D. A. Cytoplasmic poly(A) binding proteins regulate telomerase activity and cell growth in human papillomavirus type 16 E6-expressing keratinocytes J. Virol. 2010, 84, 12934-44
47. Kumar, G. R.; Shum, L.; Glaunsinger, B. A. Importin alpha-mediated nuclear import of cytoplasmic poly(A) binding protein occurs as a direct consequence of cytoplasmic mRNA depletion Mol. Cell. Biol. 2011, 31, 3113-25
48. Norman, K. L.; Sarnow, P. Herpes Simplex Virus is Akt-ing in translational control Gene. Dev. 2010, 24, 2583-6
49. Walsh, D. Manipulation of the host translation initiation complex eIF4F by DNA viruses Biochem. Soc. Trans. 2010, 38, 1511-6
50. Kudchodkar, S. B.; Yu, Y.; Maguire, T. G.; Alwine, J. C. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase J. Virol. 2004, 78, 11030-9
51. Walsh, D.; Perez, C.; Notary, J.; Mohr, I. Regulation of the translation initiation factor eIF4F by multiple mechanisms in human cytomegalovirus-infected cells J. Virol. 2005, 79, 8057-64
52. Moody, C. A.; Scott, R. S.; Amirghahari, N.; Nathan, C.-A.; Young, L. S.; Dawson, C. W.; Sixbey, J. W. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A J. Virol. 2005, 79, 5499-506
53. Arias, C.; Walsh, D.; Harbell, J.; Wilson, A. C.; Mohr, I. Activation of host translational control pathways by a viral developmental switch PLoS Pathog. 2009, 5, e1000334
54. Chuluunbaatar, U.; Roller, R.; Feldman, M. E.; Brown, S.; Shokat, K. M.; Mohr, I. Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication Gene. Dev. 2010, 24, 2627-39
55. Walsh, D.; Mohr, I. Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells Gene. Dev. 2004, 18, 660-72
56. Gingras, A. C.; Gygi, S. P.; Raught, B.; Polakiewicz, R. D.; Abraham, R. T.; Hoekstra, M. F.; Aebersold, R.; Sonenberg, N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism Gene. Dev. 1999, 13, 1422-37
57. Gingras, A. C.; Raught, B.; Gygi, S. P.; Niedzwiecka, A.; Miron, M.; Burley, S. K.; Polakiewicz, R. D.; Wyslouch-Cieszynska, A.; Aebersold, R.; Sonenberg, N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1 Gene. Dev. 2001, 15, 2852-64
58. Mothe-Satney, I.; Yang, D.; Fadden, P.; Haystead, T. A.; Lawrence, J. C. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression Mol. Cell. Biol. 2000, 20, 3558-67
59. Ayuso, M. I.; Hernández-Jiménez, M.; Martín, M. E.; Salinas, M.; Alcázar, A. New hierarchical phosphorylation pathway of the translational repressor eIF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress J. Biol. Chem. 2010, 285, 34355-63
60. Blom, N.; Gammeltoft, S.; Brunak, S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites J. Mol. Biol. 1999, 294, 1351-62
61. Karaca, G.; Anobile, J.; Downs, D.; Burnside, J.; Schmidt, C. J. Herpesvirus of turkeys: microarray analysis of host gene responses to infection Virology 2004, 318, 102-11
62. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat. Cell Biol. 2002, 4, 648-57
63. Tee, A. R.; Fingar, D. C.; Manning, B. D.; Kwiatkowski, D. J.; Cantley, L. C.; Blenis, J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13571-6
64. Steinmassl, M.; Hamprecht, K. Double fluorescence analysis of human cytomegalovirus (HCMV) infected human fibroblast cultures by flow cytometry: increase of class I MHC expression on uninfected cells and decrease on infected cells Arch. Virol. 1994, 135, 75-87
65. Hengel, H.; Esslinger, C.; Pool, J.; Goulmy, E.; Koszinowski, U. H. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells J. Gen. Virol. 1995, 76, 2987-97
66. Gobl, A. E.; Funa, K.; Alm, G. V. Different induction patterns of mRNA for IFN-alpha and -beta in human mononuclear leukocytes after in vitro stimulation with herpes simplex virus-infected fibroblasts and Sendai virus J. Immunol. 1988, 140, 3605-9
67. Sehgal, P. B.; Helfgott, D. C.; Santhanam, U.; Tatter, S. B.; Clarick, R. H.; Ghrayeb, J.; May, L. T. Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the beta 2-interferon/hepatocyte- stimulating factor/interleukin 6 gene in virus-infected human fibroblasts J. Exp. Med. 1988, 167, 1951-6
68. Kurane, I.; Janus, J.; Ennis, F. A. Dengue virus infection of human skin fibroblasts in vitro production of IFN-?, IL-6 and GM-CSF Arch. Virol. 1992, 124, 21-30
69. Lai, M. C.; Yeow, W. S.; Boyer, S. J.; Beilharz, M. W. Differential expression patterns of type I interferon subtypes in mouse embryo fibroblasts: influence of genotype and viral inducer Antiviral Res. 1994, 24, 327-40
70. Morgan, R. W.; Sofer, L.; Anderson, A. S.; Erin, L.; Sofer, L. U. C.; Anderson, A. M. Y. S.; Bernberg, E. L.; Cui, J. Induction of host gene expression following infection of chicken embryo fibroblasts with oncogenic Marek' s disease virus J. Virol. 2001, 75, 533-9
71. Shin, B.-S.; Kim, J.-R.; Walker, S. E.; Dong, J.; Lorsch, J. R.; Dever, T. E. Initiation factor eIF2γ promotes eIF2-GTP-Met-tRNA(i)(Met) ternary complex binding to the 40S ribosome Nat. Struct. Mol. Biol. 2011, 18, 1227-34
72. Dorris, D. R.; Erickson, F. L.; Hannig, E. M. Mutations in GCD11, the structural gene for eIF-2 gamma in yeast, alter translational regulation of GCN4 and the selection of the start site for protein synthesis EMBO J. 1995, 14, 2239-49
73. Alone, P. V.; Cao, C.; Dever, T. E. Translation initiation factor 2gamma mutant alters start codon selection independent of Met-tRNA binding Mol. Cell. Biol. 2008, 28, 6877-88
74. Kruger, M.; Beger, C.; Li, Q. X.; Welch, P. J.; Tritz, R.; Leavitt, M.; Barber, J. R.; Wong-Staal, F. Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8566-71
75. Feng, P.; Everly, D. N.; Read, G. S. mRNA decay during herpes simplex virus (HSV) infections: protein-protein interactions involving the HSV virion host shutoff protein and translation factors eIF4H and eIF4A J. Virol. 2005, 79, 9651-64
76. Tang, D.-J.; Dong, S.-S.; Ma, N.-F.; Xie, D.; Chen, L.; Fu, L.; Lau, S. H.; Li, Y.; Guan, X.-Y. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma Hepatology 2010, 51, 1255-63
77. He, L.-R.; Zhao, H.-Y.; Li, B.-K.; Liu, Y.-H.; Liu, M.-Z.; Guan, X.-Y.; Bian, X.-W.; Zeng, Y.-X.; Xie, D. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients Int. J. Cancer 2011, 129, 143-50